≥99%
CJC-1295 + Ipamorelin Blend
A lyophilized blend combining CJC-1295 no DAC (30 aa, 3367.97 g/mol) and Ipamorelin (5 aa, 711.85 g/mol) for in-vitro receptor co-activation studies.
1 vial × $75 each
Add 3+ to unlock
volume pricing
Pay with Visa, Mastercard, or AMEX · ACH bank transfer saves 5%
Free US shipping on orders over $200, with tracking provided.
Third-party tested
Supplied to qualified labs and institutional buyers. Institutional use & buyer eligibility
Characteristics
| Property | Value |
|---|---|
| Components | CJC-1295 no DAC (Mod GRF 1-29) + Ipamorelin |
| CJC-1295 Molecular Formula | C₁₅₂H₂₅₂N₄₄O₄₂ |
| Ipamorelin Molecular Formula | C₃₈H₄₉N₉O₅ |
| CJC-1295 Molar Mass | 3367.97 g/mol |
| Ipamorelin Molar Mass | 711.85 g/mol |
| Physical Form | Lyophilized powder blend |
| Solubility | Both components soluble in aqueous laboratory solvent |
| Organoleptic Profile | White lyophilized powder; odorless |
| Storage Conditions | Store lyophilized at -20°C; reconstituted solution stable at 2-8°C for up to 21 days |
| Composition | Lyophilized blend of Modified GRF (1-29) acetate and Ipamorelin acetate |
How is CJC-1295 + Ipamorelin Blend Used in Research?
The CJC-1295 no DAC + Ipamorelin blend is a lyophilized research formulation combining a 30-amino acid GHRH analog (3367.97 g/mol) with a 5-amino acid synthetic pentapeptide (711.85 g/mol) for in-vitro receptor co-activation studies. The blend is supplied as a laboratory research standard targeting GHRH-R and GHS-R1a binding assays in parallel. Not for use in any living organism.
Characterization workflows profile the blend in recombinant GHRH-R and GHS-R1a expression systems, with standard biochemical readouts including cAMP accumulation (Gs-cAMP-PKA pathway) and IP1/calcium-flux panels (Gq/11-PLC-calcium pathway). In cultured pituitary somatotroph cell lines, the two components can be co-applied to study convergent signaling from the two receptor systems.
Researchers use this blend as a combined reference mixture for analytical method development (HPLC/LC-MS comparability assays requiring simultaneous quantitation of both peptides) and as a two-receptor co-activation reference for functional characterization of novel GHRH or GHS analogs.
This product is supplied in a lyophilized form and requires reconstitution prior to laboratory handling. For research and laboratory use only. Not for human or veterinary consumption.
Areas of Study
Two-Receptor In-Vitro Co-Activation Studies
Applied as a combined reference mixture for parallel GHRH-R and GHS-R1a binding and functional readouts in recombinant cell systems.
Convergent Signaling Characterization
Used to profile Gs-cAMP-PKA versus Gq/11-PLC-calcium pathway readouts simultaneously in cultured somatotroph cell lines.
Receptor Selectivity Profiling
Applied in multi-receptor panels to profile each component's selectivity signature within the two-component blend.
Analytical Method Development
Serves as a combined identity, purity, and potency reference standard in HPLC and LC-MS comparability workflows.
Structural Characterization
Used in mass-spectrometry and circular-dichroism profiling of the two-component lyophilized reference standard.
References
- [1]Bowers CY, Granda R, Mohan S, et al. (2004). Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I) by a combination of the GH-releasing peptide-6 and GH-releasing hormone. Journal of Clinical Endocrinology & Metabolism, 89(10), 5174-5181.
- [2]Raun K, Hansen BS, Johansen NL, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561.
- [3]Ionescu M, Frohman LA. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology & Metabolism, 91(12), 4792-4797.
- [4]Veldhuis JD, Keenan DM, Bailey JN, et al. (2008). Novel relationships of age, visceral adiposity, insulin-like growth factor (IGF)-I and IGF binding protein concentrations to growth hormone (GH) releasing-hormone and GH releasing-peptide efficacies in men during experimental hypogonadal clamp. Journal of Clinical Endocrinology & Metabolism, 93(6), 2143-2150.
Disclaimer: The information provided is for research reference only and does not constitute medical advice. Products are sold strictly for in-vitro research use.
Certificate of Analysis (COA)
Third-Party Verified Quality
Every batch of CJC-1295 + Ipamorelin Blendis independently tested by an A2LA-accredited (ISO 17025:2017) third-party laboratory using HPLC-UV/VIS for purity and measured quantity. Each COA carries the lab's signed report and a batch-specific lot number. We publish these results publicly so you can verify exactly what you're getting.
View Lab ResultsRelated Products
GIP3
10mg – 30mg
Triple-agonist research peptide targeting GIP, GLP-1, and glucagon receptors in preclinical metabolic studies.
CJC-1295 (no DAC)
5mg – 10mg
CJC-1295 is a 30-amino acid synthetic GHRH analog with a Drug Affinity Complex modification, supplied for in-vitro receptor-binding and half-life characterization studies.
Ipamorelin
5mg – 10mg
Ipamorelin is a 5-amino acid synthetic peptide growth hormone secretagogue supplied for in-vitro GHS-R1a receptor-binding assays and selectivity profiling.
Tesamorelin
5mg – 10mg
A synthetic GHRH analog supplied as a lyophilized reference standard for in-vitro GHRH-receptor-binding assays, selectivity profiling, and analytical method development. Not for use in any living organism.
Frequently Bought Together
CJC-1295 + Ipamorelin Blend
10mg (5mg/5mg)
$75
GIP3
10mg
$100
CJC-1295 (no DAC)
5mg
$45
Bundle total
$220